The weight-loss drugs being tested in 2025: will they beat Ozempic?
In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial of its experimental drug CagriSema — a combination of semaglutide and a medicine called cagrilintide. People on CagriSema lost about 23% of their body weight in a 68-week study, outperforming both drugs when taken alone.
A study finds GLP-1 weight-loss drugs may pose vision risks, revealing an unexpected medical irony. A paradoxical insight: ...
Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...
Discover why people risk buying Ozempic and similar weight loss medications through social media, the devastating consequences, and legitimate ways to treatment ...
1don MSN
A well-known class of drugs used to manage type 2 diabetes and control weight could offer hope for patients who also struggle ...
Compounded semaglutide is legal, but it's not regulated in the same way as medications like Ozempic and Wegovy.
New restrictions and safety checks on online pharmacies that prescribing high risk drugs, such as the weight loss drugs semaglutide and tirzepatide, could have a “significant” impact on GPs’ workload, ...
The popular weight-loss drugs known as GLP-1 receptor agonists, which were originally meant to treat diabetes, surged in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback